<DOC>
	<DOCNO>NCT02756793</DOCNO>
	<brief_summary>A multicenter randomize phase II trial stereotactic body radiotherapy oligo-progressive non-small cell lung cancer . Eligible patient randomize 1:2 ratio receive standard care therapy stereotactic ablative radiotherapy ( SABR ) sit oligo-progressive lesions.Radiotherapy administer soon possible follow randomization , subject follow next disease progression . The primary outcome progression-free survival ( PFS ) .</brief_summary>
	<brief_title>Stereotactic Radiotherapy Oligo-Progressive Non-Small Cell Lung Cancer ( STOP-NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Age 18 old Willing provide inform consent Histologically confirm NonSmall Cell Lung Cancer ( NSCLC ) metastatic disease detect image . Biopsy metastasis time point prior enrollment preferred , require . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Life expectancy &gt; 3 month Patient receive treatment systemic therapy ( either cytotoxic target , include maintenance therapy ) past 6 week . This recent systemic therapy agent must deliver total least 3 month , initial partial response ( PR ) , complete response ( CR ) stable disease ( CR ) prior development oligoprogressive lesion . Oligoprogression , define Response Evaluation Criteria Solid Tumors ( RECIST ) document progression 5 individual lesion , previous radiation radiofrequency ablation site . Oligoprogression may define : Progression individual metastasis accord RECIST 1.1 criterion Unambiguous development new metastatic lesion least 5mm size Progressive enlargement know metastasis 2 consecutive image study 2 3 month apart minimum 5mm increase size baseline All site oligoprogression safely treat Maximum 3 progressing metastasis single organ system ( i.e . lung , liver , brain , bone ) , total number metastasis must 5 less Note Patients Brain Metastases : For patient brain metastasis oligoprogression elsewhere stereotactic radiation brain deem warranted , must specify prior randomization . If randomize Standard Arm , patient would receive stereotactic radiation brain . If randomize Experimental Arm , patient would receive stereotactic radiation brain body lesion Serious medical comorbidities preclude radiotherapy , ataxiatelangiectasia scleroderma . For patient oligoprogressive lesion lung thorax , include interstitial lung disease Prior radiotherapy site require treatment Malignant pleural effusion Inability treat site enlarge , oligoprogressive disease Clinical radiological evidence spinal cord compression tumor within 3mm spinal cord MRI Any condition judgment investigator would make patient inappropriate entry study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>